SEB Asset Management AB Invests $7.91 Million in Upstream Bio, Inc. $UPB

SEB Asset Management AB purchased a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB) in the 1st quarter, HoldingsChannel.com reports. The fund purchased 878,473 shares of the company’s stock, valued at approximately $7,906,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new stake in Upstream Bio in the 4th quarter worth about $29,000. Torren Management LLC acquired a new position in shares of Upstream Bio during the fourth quarter valued at approximately $30,000. BNP Paribas Financial Markets raised its holdings in shares of Upstream Bio by 229.8% during the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after acquiring an additional 2,158 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after acquiring an additional 1,440 shares in the last quarter. Finally, Empowered Funds LLC acquired a new stake in shares of Upstream Bio in the fourth quarter worth approximately $45,000.

Analyst Ratings Changes

Several analysts recently commented on the company. HC Wainwright started coverage on Upstream Bio in a research report on Wednesday, June 3rd. They set a “buy” rating and a $36.00 price target for the company. Weiss Ratings lowered Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Mizuho lowered their target price on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. Evercore lowered shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 target price for the company. in a report on Friday, March 27th. Finally, Wall Street Zen cut shares of Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $33.17.

Upstream Bio Price Performance

Shares of Upstream Bio stock opened at $6.98 on Wednesday. The stock has a market cap of $379.85 million, a P/E ratio of -2.40 and a beta of 1.23. The stock’s 50 day simple moving average is $7.35 and its 200-day simple moving average is $12.68. Upstream Bio, Inc. has a 1-year low of $5.85 and a 1-year high of $33.68.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%. The company had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $1.03 million. As a group, research analysts expect that Upstream Bio, Inc. will post -2.9 EPS for the current fiscal year.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.